DOCSLIB.ORG

Toll-Like Receptor 9 and Interferon-Gamma Receptor Signaling Suppress the B Cell Fate of Uncommitted Progenitors in Mice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toll-Like Receptor 9 and Interferon-Gamma Receptor Signaling Suppress the B Cell Fate of Uncommitted Progenitors in Mice University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2014 Toll-Like Receptor 9 and Interferon-Gamma Receptor Signaling Suppress the B Cell Fate of Uncommitted Progenitors in Mice Sheena Rose Baratono University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Allergy and Immunology Commons, Developmental Biology Commons, Immunology and Infectious Disease Commons, and the Medical Immunology Commons Recommended Citation Baratono, Sheena Rose, "Toll-Like Receptor 9 and Interferon-Gamma Receptor Signaling Suppress the B Cell Fate of Uncommitted Progenitors in Mice" (2014). Publicly Accessible Penn Dissertations. 1204. https://repository.upenn.edu/edissertations/1204 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1204 For more information, please contact [email protected]. Toll-Like Receptor 9 and Interferon-Gamma Receptor Signaling Suppress the B Cell Fate of Uncommitted Progenitors in Mice Abstract TOLL-LIKE RECEPTOR 9 AND INTFERON-GAMMA RECEPTOR SIGNALING SUPPRESS THE B CELL FATE OF UNCOMMITTED PROGENITORS IN MICE Sheena Baratono Edward M. Behrens Hyperinflammatory syndromes come in a variety of flavors with different immunogens and cytokines leading to variations in organ pathology. This inflammation can be driven by viral, autoimmune, or neoplastic conditions leading to profound and widespread organ pathology including hepatitis, fever, splenomegaly, cytokinemia and pan-cytopenias, including T and B lymphopenias. The developing immune cells in the bone marrow are known to express a variety of cytokine and inflammatory receptors yet the effects of signaling through these receptors on hematopoiesis is incomplete. Since many infectious and autoimmune syndromes result in sustained TLR9 stimulation, understanding the effects of TLR9 driven inflammation on hematopoiesis is important for both questions of pathogenesis as well as possible therapeutic interventions that might help to restore homeostasis. Utilizing in vitro and in vivo techniques, we demonstrate that B lymphopoiesis is inhibited during TLR9 driven inflammation from the Ly-6D+ CLP stage onwards with different effects inhibiting development at multiple stages across B cell development. We show that TLR9 signaling directly decreases in vitro B cell yields from CLPs, Pro and Pre B cells yet increases T cell yields. While TLR9 can inhibit B cell growth in vitro, using mixed bone marrow chimeras, we show in vivo that this TLR9 intrinsic effect is masked, likely due to other TLR9 induced inflammatory factors that also mediate decreases in B lymphopoiesis. This led us to demonstrate that IFN-γ also directly inhibits B cell differentiation in vitro as well as when induced by TLR9 in vivo. Microarray and RT- PCR analysis of Ly-6D- CLPs points to HOXa9 as an early B-cell directing transcription factor that is altered by TLR9 induced inflammation, as it and many of its known targets are decreased in Ly-6D- CLPs. Additionally EBF-1, another factor essential for initiation of the B cell program was transcriptionally decreased in Ly-6D- and Ly-6D+ CLPs. Our work demonstrates both cellular and molecular targets that lead to altered B-lymphopoiesis in sustained TLR9 driven inflammation that may be relevant in a number of infectious and autoimmune/inflammatory settings. Degree Type Dissertation Degree Name Doctor of Philosophy (PhD) Graduate Group Immunology First Advisor Edward M. Behrens Keywords B cell, inflammation, interferon, lymphopoiesis, T cell, TLR9 Subject Categories Allergy and Immunology | Developmental Biology | Immunology and Infectious Disease | Medical Immunology | Medicine and Health Sciences This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1204 TOLL-LIKE RECEPTOR 9 AND INTERFERON-GAMMA RECEPTOR SIGNALING SUPRESS THE B CELL FATE OF UNCOMMITTED PROGENITORS IN MICE Sheena Baratono A DISSERTATION in Immunology Presented to the Faculties of the University of Pennsylvania in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy 2014 Supervisor of Dissertation _____________________ Edward M. Behrens Associate Professor of Pediatrics Graduate Group Chairperson ______________________ David M. Allman Associate Professor of Pathology and Laboratory Medicine Dissertation Committee: David M. Allman, Associate Professor of Pathology and Laboratory Medicine Avinash Bhandoola, Senior Investigator National Cancer Institute Igor E. Brodsky, (Chair) Assistant Professor of Micorbiology Kathleen Sullivan, Professor of Pediatrics ACKNOWLEDGMENTS I have had an extremely rewarding learning experience throughout my graduate career. To start, I would like to thank my mentor, Edward Behrens, for all of his advice, guidance, and expertise. His flexibility to explore my interests and follow where the data leads, even if it’s not where you were expecting, have been invaluable to my development as a scientist. I would also like to thank all of the members of the Behrens and Koretzky labs for their help, support, and scientific advice over the past few years. I am especially grateful to Niansheng Chu and Lee Richardson for help with some of the experiments in this manuscript. I would like to thank Michael P. Cancro and David M. Allman for their critical review of our manuscript and Martha Jordan, Taku Kambayashi, Avinash Bhandoola, and Gary Koretzky for their support and helpful discussions. I am grateful for the scientific discussions and advice from various lab meeting groups I was a part of including the Cancro, Allman, and Laufer labs. Thank you to Igor Brodsky for chairing my thesis committee, and to the other members Dave Allman, Avinash Bhandoola, and Kate Sullivan. I would also like to thank Gary Koretzky for his guidance and support throughout the PhD. These individuals have allowed me to get the most out of my committee meetings and have guided my development as a young scientist. I would also like to thank the Immunology Graduate Group including the countless faculty and staff that have facilitated my training during my graduate career. ii I would also thank the NapCore at the Children’s Hospital of Philadelphia for their help running the microarray and technical support and the flow cytometry core at the University of Pennsylvania for technical help. Lastly, I would like to thank my family and friends for their support throughout graduate school. Their patience and support have enabled me to get through the roughest times of my training. I would like to give a special thanks to Dustin Shilling for his support and council throughout the PhD process, as well as for his encouragement and patience through the trails and excitements of graduate school. iii ABSTRACT TOLL-LIKE RECEPTOR 9 AND INTFERON-GAMMA RECEPTOR SIGNALING SUPPRESS THE B CELL FATE OF UNCOMMITTED PROGENITORS IN MICE Sheena Baratono Edward M. Behrens Hyperinflammatory syndromes come in a variety of flavors with different immunogens and cytokines leading to variations in organ pathology. This inflammation can be driven by viral, autoimmune, or neoplastic conditions leading to profound and widespread organ pathology including hepatitis, fever, splenomegaly, cytokinemia and pan-cytopenias, including T and B lymphopenias. The developing immune cells in the bone marrow are known to express a variety of cytokine and inflammatory receptors yet the effects of signaling through these receptors on hematopoiesis is incomplete. Since many infectious and autoimmune syndromes result in sustained TLR9 stimulation, understanding the effects of TLR9 driven inflammation on hematopoiesis is important for both questions of pathogenesis as well as possible therapeutic interventions that might help to restore homeostasis. Utilizing in vitro and in vivo techniques, we demonstrate that B lymphopoiesis is inhibited during TLR9 driven inflammation from the Ly-6D+ CLP stage onwards with different effects inhibiting development at multiple stages across B cell development. We show that TLR9 signaling directly decreases in vitro B cell yields from CLPs, Pro and Pre B cells yet increases T cell yields. While TLR9 can inhibit B cell growth in vitro, using mixed bone marrow chimeras, we show in vivo that this TLR9 iv intrinsic effect is masked, likely due to other TLR9 induced inflammatory factors that also mediate decreases in B lymphopoiesis. This led us to demonstrate that IFN-γ also directly inhibits B cell differentiation in vitro as well as when induced by TLR9 in vivo. Microarray and RT-PCR analysis of Ly-6D- CLPs points to HOXa9 as an early B-cell directing transcription factor that is altered by TLR9 induced inflammation, as it and many of its known targets are decreased in Ly-6D- CLPs. Additionally EBF-1, another factor essential for initiation of the B cell program was transcriptionally decreased in Ly- 6D- and Ly-6D+ CLPs. Our work demonstrates both cellular and molecular targets that lead to altered B-lymphopoiesis in sustained TLR9 driven inflammation that may be relevant in a number of infectious and autoimmune/inflammatory settings. v TABLE OF CONTENTS ACKNOWLEDGMENTS …………………………..….…………………………..….. ii ABSTRACT ……………………………………………….……………...……….…… iv TABLE OF CONTENTS ………………………………………………………......…. vi LIST OF TABLES ……………………………………………………….….……........ ix LIST OF FIGURES ……………………….….………….……………….…..…........... x CHAPTER 1 – Introduction……..……………………………….……….………........ 1 Diseases of Hyperinflammation ………………………………………….……...
Load more

Recommended publications
  • Environments of Haematopoiesis and B-Lymphopoiesis in Foetal Liver K
    Environments of haematopoiesis and B-lymphopoiesis in foetal liver K. Kajikhina1, M. Tsuneto1,2, F. Melchers1 1Max Planck Fellow Research Group ABSTRACT potent myeloid/lymphoid progenitors on “Lymphocyte Development”, In human and murine embryonic de- (MPP), and their immediate progeny, Max Planck Institute for Infection velopment, haematopoiesis and B-lym- common myeloid progenitors (CMP) Biology, Berlin, Germany; phopoiesis show stepwise differentia- and common lymphoid progenitors 2Department of Stem Cell and Developmental Biology, Mie University tion from pluripotent haematopoietic (CLP) soon thereafter (10). The first Graduate School of Medicine, Tsu, Japan. stem cells and multipotent progenitors, T- or B-lymphoid lineage-directed pro- Katja Kajikhina over lineage-restricted lymphoid and genitors appear at E12.5-13.5, for T- Motokazu Tsuneto, PhD myeloid progenitors to B-lineage com- lymphocytes in the developing thymus Fritz Melchers, PhD mitted precursors and finally differenti- (11), for B-lymphocytes in foetal liver Please address correspondence to: ated pro/preB cells. This wave of dif- (12). Time in development, therefore, Fritz Melchers, ferentiation is spatially and temporally separates and orders these different Max Planck Fellow Research Group organised by the surrounding, mostly developmental haematopoietic stages. on “Lymphocyte Development”, non-haematopoietic cell niches. We re- Three-dimensional imaging of progen- Max Planck Institute for Infection Biology, view here recent developments and our itors and precursors indicates that stem Chariteplatz 1, current contributions on the research D-10117 Berlin, Germany. cells are mainly found inside the em- E-mail: [email protected] on blood cell development. bryonic blood vessel, and are attracted Received and accepted on August 28, 2015.
    [Show full text]
  • Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection Against Classical Swine Fever Virus
    Article Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus Yusmel Sordo-Puga 1, Marisela Suárez-Pedroso 1 , Paula Naranjo-Valdéz 2, Danny Pérez-Pérez 1, Elaine Santana-Rodríguez 1, Talia Sardinas-Gonzalez 1, Mary Karla Mendez-Orta 1, Carlos A. Duarte-Cano 1, Mario Pablo Estrada-Garcia 1 and María Pilar Rodríguez-Moltó 1,* 1 Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba; [email protected] (Y.S.-P.); [email protected] (M.S.-P.); [email protected] (D.P.-P.); [email protected] (E.S.-R.); [email protected] (T.S.-G.); [email protected] (M.K.M.O.); [email protected] (C.A.D.); [email protected] (M.P.E.) 2 Central Laboratory Unit for Animal Health (ULCSA), Havana 11400, Cuba; [email protected] * Correspondence: [email protected]; Tel.: +53-7-2504419 Abstract: Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent Citation: Sordo-Puga, Y.; classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In Suárez-Pedroso, M.; Naranjo-Valdéz, order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® P.; Pérez-Pérez, D.; subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged Santana-Rodríguez, E.; 3 intranasally at five, three, and one day post-vaccination with 2 × 10 LD50 of the highly pathogenic Sardinas-Gonzalez, T.; Mendez-Orta, Cuban “Margarita” strain of the classical swine fever virus.
    [Show full text]
  • An Essential Role of UBXN3B in B Lymphopoiesis Tingting Geng Et Al. This File Contains 9 Supplemental Figures and Legends
    An Essential Role of UBXN3B in B Lymphopoiesis Tingting Geng et al. This file contains 9 supplemental figures and legends. a Viral load (relative) load Viral Serum TNF-α b +/+ Serum IL-6 Ubxn3b Ubxn3b-/- Ubxn3b+/+ 100 100 ** Ubxn3b-/- ** 10 10 IL-6 IL-6 (pg/ml) GM-CSF (pg/ml) GM-CSF 1 1 0 3 8 14 35 0 3 8 14 35 Time post infection (Days) Time post infection (Days) Serum IL-10 Serum CXCL10 Ubxn3b+/+ Ubxn3b-/- 10000 1000 +/+ -/- * Ubxn3b Ubxn3b 1000 100 IFN-γ (pg/ml) CXCL10 (pg/ml) CXCL10 100 10 0 3 8 14 35 0 3 8 14 35 Time post infection (Days) Time post infection (Days) IL-1β IL-1β (pg/ml) Supplemental Fig.s1 UBXN3B is essential for controlling SARS-CoV-2 pathogenesis. Sex- and-age matched littermates were administered 2x105 plaque forming units (PFU) of SARS-CoV-2 intranasally. a) Quantitative RT-PCR (qPCR) quantification of SARS-CoV-2 loads in the lung at days 3 and 10 post infection (p.i). Each symbol= one mouse, the small horizontal line: the median of the result. *, p<0.05; **, p<0.01, ***, p<0.001 (non-parametric Mann-Whitney test) between Ubxn3b+/+ and Ubxn3b-/- littermates at each time point. Ubxn3b+/+ Ubxn3b-/- Live Live 78.0 83.6 CD45+ CD45+ UV UV CD45 94.1 CD45 90.9 FSC-A FSC-A FSC-A FSC-A Mac Mac 23.0 38.1 MHC II MHC II CD11b Eso CD11b Eso 5.81 7.44 CD19, MHCII subset F4_80, CD11b subset CD19, MHCII subset F4_80, CD11b subset Myeloid panel Myeloid 70.1 65.6 94.2 51.1 CD19 F4/80 CD19 F4/80 Neu DC Neu DC 4.87 1.02 16.2 2.24 CD11b, Ly-6G subset CD11b, Ly-6G subset 94.9 83.3 Ly-6G Ly-6G MHC II MHC II CD11b CD11c CD11b CD11c Live Live 82.3 76.5 CD45+ CD45+ 91.1 91.3 UV UV CD45 CD45 FSC-A FSC-A FSC-A FSC-A Q1 Q2 Q1 Q2 Q1 Q2 Q1 Q2 Lymphoid panel Lymphoid 20.1 0.29 54.1 1.17 4.27 0.060 39.2 2.55 CD4 CD4 CD19 CD19 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 47.0 32.6 7.21 37.5 67.7 28.0 7.27 51.0 CD3 CD8 CD3 CD8 Supplemental Fig.s2 Dysregulated immune compartmentalization in Ubxn3b-/- lung.
    [Show full text]
  • Cells, Tissues and Organs of the Immune System
    Immune Cells and Organs Bonnie Hylander, Ph.D. Aug 29, 2014 Dept of Immunology [email protected] Immune system Purpose/function? • First line of defense= epithelial integrity= skin, mucosal surfaces • Defense against pathogens – Inside cells= kill the infected cell (Viruses) – Systemic= kill- Bacteria, Fungi, Parasites • Two phases of response – Handle the acute infection, keep it from spreading – Prevent future infections We didn’t know…. • What triggers innate immunity- • What mediates communication between innate and adaptive immunity- Bruce A. Beutler Jules A. Hoffmann Ralph M. Steinman Jules A. Hoffmann Bruce A. Beutler Ralph M. Steinman 1996 (fruit flies) 1998 (mice) 1973 Discovered receptor proteins that can Discovered dendritic recognize bacteria and other microorganisms cells “the conductors of as they enter the body, and activate the first the immune system”. line of defense in the immune system, known DC’s activate T-cells as innate immunity. The Immune System “Although the lymphoid system consists of various separate tissues and organs, it functions as a single entity. This is mainly because its principal cellular constituents, lymphocytes, are intrinsically mobile and continuously recirculate in large number between the blood and the lymph by way of the secondary lymphoid tissues… where antigens and antigen-presenting cells are selectively localized.” -Masayuki, Nat Rev Immuno. May 2004 Not all who wander are lost….. Tolkien Lord of the Rings …..some are searching Overview of the Immune System Immune System • Cells – Innate response- several cell types – Adaptive (specific) response- lymphocytes • Organs – Primary where lymphocytes develop/mature – Secondary where mature lymphocytes and antigen presenting cells interact to initiate a specific immune response • Circulatory system- blood • Lymphatic system- lymph Cells= Leukocytes= white blood cells Plasma- with anticoagulant Granulocytes Serum- after coagulation 1.
    [Show full text]
  • Haematopoiesis During Native Conditions and Immune Thrombocytopenia Progression
    Haematopoiesis During Native Conditions and Immune Thrombocytopenia Progression Oliver Herd Doctor of Philosophy University of York Biology March 2021 i Abstract The maintenance of haematopoietic stem cell (HSC) self-renewal and differentiation throughout life is essential for ongoing haematopoiesis and is highly dependent upon cytokine-cytokine receptor interactions and direct cell-cell contact between the HSC and components of the perivascular bone marrow (BM) microenvironment. Thrombopoietin (TPO) is one of two such cytokines essential for HSC self-renewal. Although the majority of TPO is produced distally by the liver, lower amounts of TPO are thought to be produced locally in the BM, directly at the site of utilisation. However, the exact cellular sources of BM derived TPO are unclear and remains an active area of research. Contrary to previous studies, the results in this thesis indicate that megakaryocytes do not express Thpo, and instead LepR+/Cxcl12-DsRedhigh BM stromal cells (BMSCs) are major sources of Thpo in mice. Immune thrombocytopenia (ITP) is an acquired autoimmune condition characterised by reduced platelet production and increased platelet destruction by sustained immune attack. In this thesis, a novel mouse model of sustained ITP was generated and the effect on the immune and haematopoietic system was assessed. Platelet destruction was antibody dependent and appeared to be primarily driven by splenic macrophages. Additionally, ITP progression was associated with considerable progenitor expansion and BM remodelling. Single cell assays using Lin-Sca1+c-Kit+CD48-CD150+ long-term HSCs (LT-HSCs) revealed elevated LT-HSC activation and proliferation in vitro. However, LT-HSC functionality was maintained as measured by in vivo serial transplantations.
    [Show full text]
  • Instant Notes: Immunology, Second Edition
    Immunology Second Edition The INSTANT NOTES series Series Editor: B.D. Hames School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK Animal Biology 2nd edition Biochemistry 2nd edition Bioinformatics Chemistry for Biologists 2nd edition Developmental Biology Ecology 2nd edition Immunology 2nd edition Genetics 2nd edition Microbiology 2nd edition Molecular Biology 2nd edition Neuroscience Plant Biology Chemistry series Consulting Editor: Howard Stanbury Analytical Chemistry Inorganic Chemistry 2nd edition Medicinal Chemistry Organic Chemistry 2nd edition Physical Chemistry Psychology series Sub-series Editor: Hugh Wagner Dept of Psychology, University of Central Lancashire, Preston, UK Psychology Cognitive Psychology Forthcoming title Physiological Psychology Immunology Second Edition P.M. Lydyard Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, University College London, London, UK A. Whelan Department of Immunology, Trinity College and St James’ Hospital, Dublin, Ireland and M.W. Fanger Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USA © Garland Science/BIOS Scientific Publishers Limited, 2004 First published 2000 This edition published in the Taylor & Francis e-Library, 2005. “To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.” Second edition published 2004 All rights reserved. No part of this book may be reproduced or
    [Show full text]
  • Antigen-Specific Induced Foxp3 Regulatory T Cells Are Generated
    Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade Ivana R. Ferrer, Maylene E. Wagener, Minqing Song, Allan D. Kirk, Christian P. Larsen, and Mandy L. Ford1 Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322 Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved November 4, 2011 (received for review April 7, 2011) Blockade of the CD40/CD154 pathway potently attenuates T-cell in vivo accumulation of Treg and deletion of graft-specific ef- responses in models of autoimmunity, inflammation, and trans- fectors after CD40/CD154 blockade has not been investigated. plantation. Indeed, CD40 pathway blockade remains one of the To address these questions, we used an ovalbumin (OVA)- most powerful methods of prolonging graft survival in models of expressing transgenic mouse model (20), which allowed us to di- + + transplantation. But despite this effectiveness, the cellular and rectly track both donor-reactive CD4 and CD8 T-cell responses molecular mechanisms underlying the protective effects of CD40 simultaneously over time. Although previous studies have used pathway blockade are incompletely understood. Furthermore, the transgenic models to assess the degree of T-cell deletion after CD154/CD40 blockade (16, 21), none has systematically inter- relative contributions of deletion, anergy, and regulation have not + been measured in a model in which donor-reactive CD4+ and CD8+ rogated the impact of anti-CD154 on the kinetics of both CD4 and CD8+ T-cell deletion and acquisition of effector function. T-cell responses can be assessed simultaneously. To investigate the fi Our results indicated that although CD40/CD154 blockade alone impact of CD40/CD154 pathway blockade on graft-speci c T-cell delayed donor-reactive CD4+ and CD8+ T-cell expansion and responses, a transgenic mouse model was used in which recipients differentiation, the addition of DST was required for antigen- fi + + containing ovalbumin-speci cCD4 and CD8 TCR transgenic T specific T-cell deletion.
    [Show full text]
  • Evolutionary Divergence and Functions of the Human Interleukin (IL) Gene Family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W
    UPDATE ON GENE COMPLETIONS AND ANNOTATIONS Evolutionary divergence and functions of the human interleukin (IL) gene family Chad Brocker,1 David Thompson,2 Akiko Matsumoto,1 Daniel W. Nebert3* and Vasilis Vasiliou1 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Denver, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267–0056, USA *Correspondence to: Tel: þ1 513 821 4664; Fax: þ1 513 558 0925; E-mail: [email protected]; [email protected] Date received (in revised form): 22nd September 2010 Abstract Cytokines play a very important role in nearly all aspects of inflammation and immunity. The term ‘interleukin’ (IL) has been used to describe a group of cytokines with complex immunomodulatory functions — including cell proliferation, maturation, migration and adhesion. These cytokines also play an important role in immune cell differentiation and activation. Determining the exact function of a particular cytokine is complicated by the influence of the producing cell type, the responding cell type and the phase of the immune response. ILs can also have pro- and anti-inflammatory effects, further complicating their characterisation. These molecules are under constant pressure to evolve due to continual competition between the host’s immune system and infecting organisms; as such, ILs have undergone significant evolution. This has resulted in little amino acid conservation between orthologous proteins, which further complicates the gene family organisation. Within the literature there are a number of overlapping nomenclature and classification systems derived from biological function, receptor-binding properties and originating cell type.
    [Show full text]
  • Interferon Gamma Release Assay (IGRA) Interferon Gamma Release Assay (IGRA) Is a Blood Test That Has Recently Been Introduced As Another Method to Diagnose LTBI
    Section 4: TB Screening These cases also included patients that did not have previous exposure to tuberculin. It is imperative that health care providers should have Epinephrine Hypochloride solution (1:1000) and other appropriate agents available for immediate use in the case of a hypersensitivity reaction. As per NACI, recommendations all patients must be monitored for 15 minutes after inoculation. Interferon Gamma Release Assay (IGRA) Interferon gamma release assay (IGRA) is a blood test that has recently been introduced as another method to diagnose LTBI. Therefore, it can complement the TST in certain situations. In general, IGRAs are more specific than the TST in populations vaccinated with BCG, especially if BCG is given after infancy or multiple times. When a person is exposed to MTB it produces many immune cells, which produce various proteins. Among these proteins are interferon gamma or IFN-y. The interferon gamma release assay (IGRA) is a blood test that measures IFN-y. Therefore, if a person has been exposed and infected with TB, IFN-y can be detected with this test. There are two IGRA tests used in Canada, the T-SPOT.TB test and the QuantiFERON®-TB Gold test. Provincial Laboratory (ProvLab) Alberta uses QuantiFERON®-TB Gold (QFT) test in the NWT. Specimens must be received by the regional laboratory and incubated for 16–24 hours. This limits availability of this test in the NWT. IGRA can only be ordered through the Office of the Chief Public Health Officer and Stanton Regional Hospital Specialists who are involved in TB management and treatment. IGRAs require laboratories with adequate equipment and trained personnel to perform the assays.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • Plasma Cells: Finding New Light at the End of B Cell Development Kathryn L
    © 2001 Nature Publishing Group http://immunol.nature.com REVIEW Plasma cells: finding new light at the end of B cell development Kathryn L. Calame Plasma cells are cellular factories devoted entire- Upon plasma cell differentiation, there is a marked increase in ly to the manufacture and export of a single prod- steady-state amounts of Ig heavy and light chain mRNA and, when 2 uct: soluble immunoglobulin (Ig). As the final required for IgM and IgA secretion, J chain mRNA . Whether the increase in Ig mRNA is due to increased transcription, increased mediators of a humoral response, plasma cells mRNA stability or, as seems likely, both mechanisms, remains con- play a critical role in adaptive immunity.Although troversial2. There is also an increase in secreted versus membrane intense effort has been devoted to studying the forms of heavy chain mRNA, as determined by differential use of poly(A) sites that may involve the availability of one component of regulation and requirements for early B cell the polyadenylation machinery, cleavage-stimulation factor Cst-643. development, little information has been avail- To accommodate translation and secretion of the abundant Ig able on plasma cells. However, more recent mRNAs, plasma cells have an increased cytoplasmic to nuclear ratio work—including studies on genetically altered and prominent amounts of rough endoplasmic reticulum and secreto- ry vacuoles. mice and data from microarray analyses—has Numerous B cell–specific surface proteins are down-regulated begun to identify the regulatory cascades that upon plasma cell differentiation, including major histocompatibility initiate and maintain the plasma cell phenotype. complex (MHC) class II, B220, CD19, CD21 and CD22.
    [Show full text]
  • 2010 Hepatitis C Treatment Updates
    2010 Hepatitis C Treatment Updates Summer 2010 Treatment Options Conventional Interferon Alone (Monotherapy) Studies in adults have demonstrated that monotherapy with conventional interferon is effective for adults 10-15% of the time. Although children typically respond better than adults to this treatment (27% for genotype 1 and 71% for genotype 2 and 3), subsequent study has confirmed that using conventional interferon in combination with ribavirin produces better treatment outcomes for both adults and children. Thus, conventional interferon alone is no longer recommended for the majority of children requiring HCV therapy. Conventional Interferon Alpha-2b in Combination with Ribavirin (Rebetron for Children) Rebetron was the first drug to be FDA-approved to treat children with hepatitis C. It’s approved for use in children between the ages of 5 and 16 years. Rebetron is a combination drug that contains both Intron A (an interferon alfa-2b) and Rebetol (which is ribavirin). Rebetron is administered as a weight-based dose of oral Rebetol that is taken twice a day. (Rebetol should never be used alone to treat hepatitis C.) The Intron A portion of the treatment is a subcutaneous injection that is given three times weekly for 24 to 48 weeks. Sometimes, problems with anemia or depression can develop with this treatment. When this occurs, doses should be reduced temporarily or permanently until the problem is reversed. Additionally, if uncontrollable thyroid abnormalities (such has hypothyroidism) occur, treatment should be discontinued. Use of conventional interferon alpha-2b in combination with ribavirin has been shown to improve treatment outcomes in adults when compared to using conventional interferon alone.
    [Show full text]